Plexxicon

This week, Certara said that Plexxikon has selected its D360 software solution to support data access and analysis for its drug discovery projects.

Since BRAF inhibitors such as Roche/Plexxicon's vemurafenib, or PLX 4032, are currently in clinical trials for melanoma patients, the authors think there could be a rapid transition of their findings to the clinic.

By exploring a treatment strategy that involves Roche/Plexxikon's investigational pharmacogenomically targeted drug vemurafenib and Bristol-Myers Squibb's newly approved melanoma treatment Yervoy, two large drug developers are hoping to further improve outcomes for a genomically defined patient population.

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.